• Cosmos Health’s Cana Laboratories acquired international patent application WO2025108566A1 from Cloudpharm.
• Cana started seeking national and regional patent protection across key international markets.
• The deal expands the group’s IP portfolio to support next-generation drug and consumer-health product development.
• Cana also plans to increase nanotechnology investments, leveraging its European GMP-licensed, EMA-certified manufacturing platform.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cosmos Health Inc. published the original content used to generate this news brief on June 08, 2026, and is solely responsible for the information contained therein.